Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer
Crossref DOI link: https://doi.org/10.1007/s10549-014-3102-8
Published Online: 2014-08-17
Published Print: 2014-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Madden, Julie M.
Mueller, Kelly L.
Bollig-Fischer, Aliccia
Stemmer, Paul
Mattingly, Raymond R.
Boerner, Julie L.
Text and Data Mining valid from 2014-08-17